Merck Stock News

The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

Medtronic and Merck are innovative healthcare leaders. Both are developing new products to keep sales growing.

Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.

Merck said on Friday its drug Keytruda, in combination with chemoradiotherapy, met the main goal in a late-stage study in newly diagnosed patients with high-risk locally advanced cervical cancer.

Merck (MRK) concluded the recent trading session at $120.51, signifying a -1.35% move from its prior day's close.

Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.

The month of March has a reputation for being among the more volatile ones for the stock market. The NCAA basketball tournament known as March Madness also occurs during the month.

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck & Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a single-dose regimen compared to the

Both of these healthcare giants are leaders in their industries and faithful dividend payers. AbbVie is dealing with short-term challenges, but the strength of its underlying business remains intact.

Merck (MRK) reachead $123.99 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Barclays 26th Annual Global Healthcare Conference.